The total return over the past 12 months is -7.96% vs. +16.94% for the S&P 500. So far it's up +28.44% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (7.96%) | (22.71%) | (67.06%) | (55.97%) | N/A | N/A |
| Total Return CAGR | (7.96%) | (22.71%) | (67.06%) | (55.97%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Kiora Pharmaceuticals, Inc. (KPRX)
| Year | Start price | End price | KPRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.97 | $2.53 | +28.44% | +14.51% | +13.93% |
| 2025 | $3.30 | $1.97 | (40.30%) | +17.72% | (58.02%) |
| 2024 | $4.70 | $3.30 | (29.79%) | +24.89% | (54.68%) |
| 2023 | $30.87 | $4.70 | (84.78%) | +26.19% | (110.97%) |
| 2022 | $543.60 | $30.87 | (94.32%) | (18.17%) | (76.15%) |
| 2021 | $1,774.80 | $543.60 | (69.37%) | +28.74% | (98.11%) |
| 2020 | $3,607.20 | $1,774.80 | (50.80%) | +18.37% | (69.17%) |
| 2019 | $2,511.54 | $3,607.20 | +43.63% | +31.22% | +12.41% |
| 2018 | $5,778.00 | $2,511.54 | (56.53%) | (4.56%) | (51.97%) |
| 2017 | $8,802.00 | $5,778.00 | (34.36%) | +21.70% | (56.06%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
